ClinicalTrials.gg
RecruitingNCT07113288AHIBMI PASUpdated Mar 27, 2026

Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study

An observational study in Obstructive Sleep Apnea (OSA), sponsored by Inspire Medical Systems, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Inspire Medical Systems, Inc. · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc. — 5 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · Inspire Medical Systems, Inc..

Started
2025
with 2 others
Observational
4 of 13
3 open now
Registered
13th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc., this one is one of 3 that started in 2025, is one of 4 observational ones, and was the 13th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

5 of the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc. are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc., or all of them as a file.
02

Study summary

The purpose of this observational clinical study is to provide evaluation of long-term safety and effectiveness in a newly expanded patient population including patients with a higher AHI and a higher BMI.

Read the detailed description

This post-approval study is a condition of FDA approval and will collect long-term safety and effectiveness data on an expanded population that includes patients with very severe obstructive sleep apnea (65\<AHI≤100 events/hr), as well as those with a higher BMI (32\<BMI≤40 kg/m2). Participants will be implanted with a commercially available Inspire UAS System. In addition, participants will receive a patient remote which is used to initiate therapy each night.

03

Conditions studied

  • Obstructive Sleep Apnea (OSA)

Keywords

  • Obstructive Sleep Apnea
  • OSA
  • Inspire
  • AHI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A post-market sample selected from enrolling center's real-world patient population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is at least 18 years of age;
  2. Subject has a diagnosis of severe OSA (65 ≤ AHI ≤ 100) based on a recent sleep study (within 12 months) OR Subject has a diagnosis of moderate to severe OSA (15≤AHI≤100) AND a baseline of 32\<BMI≤40 kg/m2;
  3. Subject has documented failure of, or intolerance to, positive airway pressure treatments (such as CPAP or BPAP machines; NOTE: PAP failure is defined as an inability to eliminate OSA (AHI > 15 despite PAP usage). PAP intolerance is defined as the inability to use PAP (> 5 nights per week, 4 hours of usage per night) or unwillingness to use PAP (e.g. patient returns the PAP system after attempting to use it).
  4. Subject is willing and able to have stimulation hardware permanently implanted and to use the patient remote to activate the stimulation;
  5. Subject is willing and able to return for follow-up visits, undergo sleep studies (including in-lab and at-home), and complete questionnaires related to the study;
  6. Subject is willing and able to provide .

Exclusion criteria

Exclusion Criteria:

  1. Subject has a combination of central + mixed apneas > 25% of the total apnea-hypopnea index (AHI) based on a recent sleep study (within 12 months);
  2. Subject has any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate;
  3. Subject has any condition or procedure that has compromised neurological control of the upper airway;
  4. Subject is unable or does not have the necessary assistance to operate the patient remote;
  5. Subject is pregnant or plans to become pregnant;
  6. Subject has an implantable device that may be susceptible to unintended interaction with the Inspire System;
  7. Subject has a terminal illness with \< 12 months;
  8. Any other reason the investigator deems the subject is unfit for participation in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • High AHI

    Following patients with 65\<AHI≤100 events/hr after Inspire Implantation for a period of 5 years

    Device: Inspire® UAS System

  • High BMI

    Following patients with 32\<BMI≤40 kg/m2 after Inspire Implantation for a period of 5 years

    Device: Inspire® UAS System

Interventions

  • DeviceInspire® UAS System

    Participants will be implanted with a commercially available Inspire® UAS System. In addition, participants will receive a patient remote which is used to initiate therapy each night.

06

What researchers measure

Primary outcomes

  1. Incidence of Procedure and/or Device Related Adverse Events (Safety and Tolerability)

    Procedure-related Adverse Events; Device-related Adverse Events

    Time frame: 5 years post-implant

Secondary outcomes

  1. Change in Apnea Hypopnea Index Over Time

    Evaluation of improvement in Apnea Hypopnea Index (AHI) over time: baseline (pre-implant) AHI compared to AHI after implant (collected and reported at annual study visits)

    Time frame: 5 years post-implant

  2. Body Mass Index

    Body Mass Index will be collected at each yearly follow-up visit.

    Time frame: 5 years post-implant

  3. Change in Oxygen Desaturation Index (ODI) Over Time

    Evaluation of improvement in Oxygen Desaturation Index (ODI) over time: baseline (pre-implant) ODI compared to ODI after implant (collected and reported at annual study visits)

    Time frame: 5 years post-implant

  4. Change in T90 (defined as total sleep time spent with arterial oxygen saturation (SaO2) < 90%) Over Time

    Evaluation of improvement in T90 (defined as total sleep time spent with arterial oxygen saturation (SaO2) \< 90%) over time: baseline (pre-implant) T90 compared to T90 after implant (collected and reported at annual study visits)

    Time frame: 5 years post-implant

  5. Change in Epworth Sleepiness Scale (ESS) Over Time

    Evaluation of improvement of Epworth Sleepiness Scale (ESS) over time: baseline (pre-implant) ESS compared to ESS after implant (collected and reported at annual study visits)

    Time frame: 5 years post-implant

Other outcomes

  1. Evaluation of Therapy Usage and Adherence Over Time

    Therapy usage - reported as hours of use per week, is recorded by the Inspire UAS system and will be captured during the device check at the 6M and annual (1-5 year) study visits. This value will be used to quantify device use and adherence over time.

    Time frame: 5 years post-implant

  2. Change in Patient Satisfaction Over Time

    A patient satisfaction survey, designed to collect information about the patient's experience with the Inspire UAS system, will be collected at the 6M and annual (1-5 year) study visits. This survey will provide information about relative satisfaction with the therapy over time.

    Time frame: 5 years post-implant

07

Study locations

5 of 5 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2032, 77 months after the start.

Of 36 industry-sponsored observational studies under Sleep Apnea, Obstructive, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 93. This study's planned 77 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
Aug 8, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Jan 1, 2032
CompletionEst.
Jan 1, 2032
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07113288
Lead sponsor
Inspire Medical Systems, Inc.
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Jul 31, 2025
Primary completion
Jan 1, 2032 (estimated)
Completion
Jan 1, 2032 (estimated)
Last update
Mar 27, 2026

Study contacts

Gwen Gimmestad
Contact
gwengimmestad@inspiresleep.com
763-392-9966

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion